Literature DB >> 27159948

Immunohistological Expression of p16INK4a is Commonly Present Both in Benign and Malignant Sweat Gland Neoplasias.

Jun Tsujita, Yumiko Kaku, Toshio Ichiki, Ayaka Eto, Hiromi Maemura, Akiko Otsuka, Risa Nakaie, Noriko Kitagawa, Yuka Morioka, Tomoyo Matsuda, Maiko Yoshida, Masutaka Furue.   

Abstract

The expression of p16INK4a has been reported to be a significant marker for malignant transformation of epidermal tumors. However, little is known about sweat gland tumors. We examined the immunohistological expression of p16INK4a in benign and malignant sweat gland tumors. The ductal and acrosyringial portion of normal eccrine glands were positively stained with p16INK4a while it was negative in the normal epidermis. Moderate to strong expression of p16INK4a was found in 16 of 17 eccrine poromas, 4 of 5 hidradenomas, 3 of 3 syringocystadenoma papilliferums, 2 of 2 mixed tumors, and 3 of 3 syringomas. The p16INK4a expression was observed focally or diffusely in 4 of 4 porocarcinomas, 4 of 4 apocrine carcinomas and 12 of 17 extramammary Paget's diseases. We conclude that the p16INK4a expression is not a good marker for dictating malignant transformation of sweat gland tumors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 27159948

Source DB:  PubMed          Journal:  Fukuoka Igaku Zasshi        ISSN: 0016-254X


  2 in total

1.  Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma.

Authors:  My Linh Thibodeau; Melika Bonakdar; Eric Zhao; Karen L Mungall; Caralyn Reisle; Wei Zhang; Morgan H Bye; Nina Thiessen; Dustin Bleile; Andrew J Mungall; Yussanne P Ma; Martin R Jones; Daniel J Renouf; Howard J Lim; Stephen Yip; Tony Ng; Cheryl Ho; Janessa Laskin; Marco A Marra; Kasmintan A Schrader; Steven J M Jones
Journal:  NPJ Precis Oncol       Date:  2018-03-19

2.  p16INK4a Expression in Porokeratosis.

Authors:  Miki Uryu; Masutaka Furue
Journal:  Ann Dermatol       Date:  2017-05-11       Impact factor: 1.444

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.